



SIDDS 2023

Seoul International Digestive Disease Symposium 2023

In Conjunction with the Annual Meeting of the Korean Society of Gastroenterology



April 8-9, 2023 Hybrid congress

Name	TAE IL KIM
Affiliation	Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine
Country	Korea
Major Field	Intestinal epithelial biology, Intestinal stem cell, Cancer stem cell, Organoid, Microenvironment, Chemoprevention, Familial and hereditary intestinal neoplasia, Prevention and treatment of colorectal neoplasia

Educational Background

1985-1991 Medical Degree, Yonsei University College of Medicine

1993-1995 Master course of Medical science, Graduate School, Yonsei University, Seoul, Korea

1995-2002 Ph. D. course of Medical science, Graduate School, Yonsei University, Seoul, Korea

Professional Experience

2002.3-2007.2 Assistant Professor of Internal Medicine, Division of Gastroenterology, Yonsei University College of Medicine

2006.8-2008.7 Research fellow, Post-doc, Division of Gastroenterology, Vanderbilt University Medical Center, TN, USA

2007.3-2012.2 Associate Professor of Internal Medicine, Division of Gastroenterology, Yonsei University College of Medicine

2012.3-present Professor of Internal Medicine, Division of Gastroenterology, Yonsei University College of Medicine

2014.5-2022.2 Director of Yonsei Cancer Prevention Center, Yonsei Cancer Center, Severance Hospital

2018.12-2019.12 President of Korean Society of Cancer Prevention

2021.3-present Director of Division of Gastroenterology, Director of Yonsei Institute of Gastroenterology, Director of Digestive Disease Center, Severance Hospital, Yonsei University College of Medicine

2021.4-present Vice president of KASID (Korean Association for the Study of Intestinal Diseases)

Main Scientific Publications

1. Tumor-Suppressive Effect of Metformin via the Regulation of M2 Macrophages and Myeloid-Derived Suppressor Cells in the Tumor Microenvironment of Colorectal Cancer. Kang J, Kim TI, et al. *Cancers* 2022;14(12):2881.

2. MRI assessment of glutamine uptake correlates with the distribution of glutamine transporters and cancer stem cell markers. Seo Y, Kim TI, et al. *Scientific Reports* 2022;12(1):5511.

3. Application of multigene panel testing in patients with high risk for hereditary colorectal cancer: a descriptive report on genotype-phenotype correlation. Park JS, Kim TI, et al. *Diseases of the Colon & Rectum* 2022;65(6):793-803.

4. Metformin and Niclosamide Synergistically Suppress Wnt and YAP in APC-Mutated Colorectal Cancer. Kang HE, Seo Y, Yun JS, et al. *Cancers* 2021; 13(14): 3437.

5. The Effect of Metformin in Treatment of Adenomas in Patients with Familial Adenomatous



SIDDS 2023

Seoul International Digestive Disease Symposium 2023

In Conjunction with the Annual Meeting of the Korean Society of Gastroenterology

April 8-9, 2023 Hybrid congress



- Polyposis. Park JJ, Kim BC, Hong SP, et al. *Cancer Prevention Research* 2021;14(5): 563-572.
6. IL-6 and IL-8, secreted by myofibroblasts in the tumor microenvironment, activate HES1 to expand the cancer stem cell population in early colorectal tumor. Kim B, Seo Y, Kwon J, et al. *Molecular Carcinogenesis* 2021;60(3): 188-200.
7. *Fusobacterium nucleatum* in biopsied tissues from colorectal cancer patients and alcohol consumption in Korea. Kim M, Lee S, Choi S, et al. *Scientific Reports* 2020;10(1): 19915.
8. Metformin Suppresses Cancer Stem Cells through AMPK Activation and Inhibition of Protein Prenylation of the Mevalonate Pathway in Colorectal Cancer. Seo Y, Kim J, Park SJ, et al. *Cancers* 2020;12(9): 2554.
9. mTOR Signaling Combined with Cancer Stem Cell Markers as a Survival Predictor in Stage II Colorectal Cancer. Chang JY, Kim JH, Kang J, et al. *Yonsei Med J* 2020;61(7): 572-578.
10. Survival Benefit for Metformin Through Better Tumor Response by Neoadjuvant Concurrent Chemoradiotherapy in Rectal Cancer. Kim JM, Park JW, Lee JH, et al. *Diseases of the Colon & Rectum* 2020;63(6): 758-768.
11. Next-generation sequencing with comprehensive bioinformatics analysis facilitates somatic mosaic APC gene mutation detection in patients with familial adenomatous polyposis. Kim B, Won D, Jang M, et al. *BMC Medical Genomics* 2019;12(1): 103.
12. Outcomes of stent insertion and mortality in obstructive stage IV colorectal cancer patients through 10 year duration. Park YE, Park Y, Park SJ, et al. *Surgical Endoscopy* 2019;33(4): 1225-1234.
13. Resting heart rate is an independent predictor of advanced colorectal adenoma recurrence. Park J, Kim JH, Park Y, et al. *PLOS ONE* 2018;13:e0193753.
14. Effects of metformin on colorectal cancer stem cells depend on alterations in glutamine metabolism. Kim JH, Lee KJ, Seo Y, et al. *Sci Rep* 2018;8:409.
15. Postoperative adjuvant chemotherapy is associated with a lower incidence of colorectal adenomas in patients with previous colorectal cancer. Lee HS, Kim SB, Lee HJ, et al. *Gastrointest Endosc* 2018;87:688-94.e2.
16. Sex-dependent difference in the effect of metformin on colorectal cancer-specific mortality of diabetic colorectal cancer patients. Park JW, Lee JH, Park YH, et al. *World Journal of Gastroenterology* 2017;23:5196-205.
17. The effects of physical activity and body fat mass on colorectal polyp recurrence in patients with previous colorectal cancer. Park J, Kim JH, Lee HJ, et al. *Cancer Prevention Research* 2017;10:478-84.
18. The effect of metformin on the recurrence of colorectal adenoma in diabetic patients with previous colorectal adenoma. Han MS, Lee HJ, Park SJ, et al. *Int J of Colorectal Dis*, 2017;32:1223-6.
19. Tumor characteristics associated with malignant large bowel obstruction in stage IV colorectal cancer patients undergoing chemotherapy. Kim DH, Kim B, Choi JH, et al. *International Journal of Colorectal Disease* 2016;31:1767-74.
20. Long-Term Effects of Bone Marrow-Derived Mesenchymal Stem Cells in Dextran Sulfate Sodium-Induced Murine Chronic Colitis. Lee HJ, Oh SH, Jang HW, et al. *Gut Liver* 2016;10:412-9.
21. High-risk metachronous polyps are more frequent in patients with traditional serrated adenomas than in patients with conventional adenomas: a multicenter prospective study. Yoon JY, Kim HT, Hong SP, et al. *Gastrointestinal Endoscopy* 2015;82:1087-93.
22. Risk Factors for Recurrent High-Risk Polyps after the Removal of High-Risk Polyps at



SIDDS 2023

Seoul International Digestive Disease Symposium 2023

In Conjunction with the Annual Meeting of the Korean Society of Gastroenterology

April 8-9, 2023 Hybrid congress



- Initial Colonoscopy. Jang HW, Park SJ, Hong SP, et al. *Yonsei Med J* 2015;56:1559-65.
23. Nonsteroidal anti-inflammatory drugs suppress cancer stem cells via inhibiting PTGS2 (cyclooxygenase 2) and NOTCH/HES1, and activating PPARG in colorectal cancer. Moon CM, Kwon J-H, Kim JS, Oh S-H, et al. *International Journal of Cancer* 2014;134:519-529.
24. Differential expression of CD133 based on microsatellite instability status in human colorectal cancer. Park JJ, Kwon J-h, Oh S-H, et al. *Molecular Carcinogenesis* 2014;53:E1-E10.
25. Chemopreventive drugs: Mechanisms via inhibition of cancer stem cells in colorectal cancer. Kim TI. *World J Gastroenterol* 2014;20:3835-46.
26. Metformin use is associated with a decreased incidence of colorectal adenomas in diabetic patients with previous colorectal cancer. Lee JH, Jeon SM, Hong SP, et al. *Digestive and Liver Disease* 2012;44:1042-7.
27. Myofibroblast keratinocyte growth factor reduces tight junctional integrity and increases claudin-2 levels in polarized Caco-2 cells. Kim TI, Poulin EJ, Blask E, et al. *Growth Factors* 2012;30:320-32.
28. The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Lee JH, Kim TI, Jeon SM, et al. *Int J Cancer*. 2012;131:752-9.
29. The role of myofibroblasts in upregulation of S100A8 and S100A9 and the differentiation of myeloid cells in the colorectal cancer microenvironment. Kim JH, Oh S-H, Kim E-J, et al. *Biochem Biophys Res Comm* 2012;423:60-6.
30. Comparison of a newly designed double-layered combination covered stent and D-weave uncovered stent for decompression of obstructive colorectal cancer: a prospective multicenter study. Moon CM, Kim TI, Lee MS, et al. *Dis Colon Rectum*. 2010;53(8):1190-6.
31. Adherens junction-dependent PI3K/Akt activation induces resistance to genotoxin-induced cell death in differentiated intestinal epithelial cells. Chae B, Yang KM, Kim TI, Kim WH. *Biochem Biophys Res Comm* 2009;378:738-743.